Ned Sharpless, MDMany other @theNCI-supported trials and research are being presented at #ASTRO2020. For example, a molecular evaluation of the Children’s Oncology Group’s (@COGorg) #Medulloblastoma trial. #PediatricCancer #ChildhoodCancer #PediatricOncology
Ned Sharpless, MDDr. Norman Coleman from @theNCI’s @NCIResearchCtr will deliver several presentations at #ASTRO2020, many focusing on his global leadership in #RadiationOncology, such as work addressing #HealthDisparities in international #CancerCare.
Radiation oncologists from around the globe meet to discuss scientific advances in cancer management.
Ned Sharpless, MDThe virtual American Society of Radiation Oncology (#ASTRO2020) meeting begins this weekend! @theNCI has representation at the meeting and also supports much of the research being presented. @ASTRO_org
PURPOSE Therapeutically actionable molecular alterations are widely distributed across cancer types. The National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial was designed to evaluate targeted therapy antitumor activity...
Ned Sharpless, MDNew NCI-MATCH Trial report in @ASCO_pubs JCO shows promise of moving #PrecisionOncology to the community level. With tumor biopsy specimens from >5900 patients across >1100 sites, this is the largest #PrecisionMedicine trial of its kind! #CommunityOncology
Ned Sharpless, MDThe nine @CancerGrand Challenges focus on cell #phenotypes, #macromolecules, #senescence, #ecigarettes, #inflammation, solid tumors in #ChildhoodCancer, extrachromosomal DNA (#ecDNA), cancer cell #dormancy, and #cachexia. Learn more about each challenge
Ned Sharpless, MDToday @theNCI and @CR_UK are announcing nine new #CancerGrandChallenges as part of our global interdisciplinary partnership to seek bold and novel #CancerResearch ideas. We are thrilled to join CRUK in this wonderful collaborative partnership!
A nonprofit, nonpartisan organization working towards effective government for the American people.
Ned Sharpless, MDCongratulations, Dr. Pastan! @theNCI is proud to have you on our team. Ira will be recognized with other honorees, including @NIH@NIAIDNews’ Dr. Anthony Fauci, TONIGHT (Oct. 5) @ 8PM ET. Details on how to watch the ceremony here
This cross-sectional study examines changes in the number of patients with newly identified cancer before and during the coronavirus disease 2019 (COVID-19) pandemic in the United States.
Ned Sharpless, MD#ICYMI: August @JAMANetworkOpen research letter shows “a significant decline in newly identified patients with 6 common types of cancer” during the early months of the #COVID19 #pandemic. Don’t delay medical appointments if you are experiencing symptoms!
In cells with microsatellite instability, expanded TA-dinucleotide repeats form cruciform structures that stall replication forks and cause chromosome shattering in the absence of the WRN helicase.
Ned Sharpless, MDGreat paper from the @theNCI @NCIResearchCtr. Now we know at least one thing the WRN helicase does. An obvious drug target for MSI-high cancers. Repeat expansions confer WRN dependence in microsatellite-unstable cancers | Nature
The National Cancer Institute and the National Institute of Biomedical Imaging and Bioengineering have awarded seven contracts to companies and academic institutions to develop digital health solutions, like smartphone apps, wearable devices, and...
Ned Sharpless, MD@theNCI and @NIBIBgov, both institutes of the @NIH, have awarded seven contracts to companies and academic institutions to develop Digital Health Solutions to help address the #COVID19 pandemic.
In this NCI Bottom Line blog, Dr. Singer expands on the August 27 partnership launch between NCI and Cancer Research UK (CRUK) to fund the Cancer Grand Challenges program. In launching Cancer Grand Challenges, NCI and CRUK are seeking novel and...
Ned Sharpless, MDBottom line: #CancerGrandChallenges, an international partnership between @theNCI and @CR_UK, will support global multidisciplinary teams of scientists in their work to address some of the most profound and unresolved questions in #CancerResearch.
With the nation’s support, nothing will stop NCI from advancing our understanding of cancer and reducing its burden—not just for some, but for all people. While contributing our scientific expertise to the current public health crisis, we remain...
Ned Sharpless, MD#CancerResearch has been fueled by patients pushing for cures and scientists not giving up. Nothing will stop us from advancing our understanding of cancer to reduce its burden. Read more of my Annual Plan & Budget Proposal Director’s Message: go.usa.gov/xG398 #NCIFuture
Now that patients and clinicians have had a taste, the appetite for enshrining the Trump administration’s expansion of telemedicine in law will never be greater. It has taken a crisis to push us to this new frontier; Congress should not let us go...
Ned Sharpless, MDIf you are interested in the care of people with cancer, this by @SeemaCMS is worth reading. The telemedicine genie is out of the bottle
During National Childhood Cancer Awareness Month, we honor the memory of the precious children and adolescents lost to cancer, and we pray for their families and friends as they remember their loved ones. We recommit to providing help, compassion,...
Ned Sharpless, MDSeptember is National Childhood Cancer Awareness Month, an important reminder that even the youngest amongst us suffer from #cancer. Supporting and advancing #ChildhoodCancer research is one of our priorities at @theNCI. #ChildhoodCancerAwarenessMonth
Survival after CRC diagnosis at a young age is significantly worse among NHBs compared with NHWs, even among patients with early-stage disease. Further study is needed to determine whether differences in tumor biology and/or treatment are associated...
Ned Sharpless, MDAs with many other cancers, there are significant #healthdisparities in mortality rates—Black patients are more likely to die of #coloncancer at all stages of disease than white patients. We must continue work to overcome these disparities.